Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation.

Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation.

Pancreatic adenocarcinoma, a desmoplastic disease, is the fourth leading cause of cancer-related death in the Western world due, in large part, to locally invasive primary tumor growth and ensuing metastasis. SPARC is a matricellular protein that governs extracellular matrix (ECM) deposition and mat...

Full description

Bibliographic Details
Main Authors: Shanna A Arnold, Lee B Rivera, Juliet G Carbon, Jason E Toombs, Chi-Lun Chang, Amy D Bradshaw, Rolf A Brekken
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3279359?pdf=render

Internet

http://europepmc.org/articles/PMC3279359?pdf=render

Similar Items